Replidyne has filed for a $100 million IPO. The Louisville, CO biotech company has been backed by George Soros' venture group. Replidyne hit an important milestone when the company filed an NDA for its new antibiotic last December. The FDA accepted it in February. Replidyne is looking for FDA approval for faropenem medoxomil as a therapy for acute bacterial sinusitis, community-acquired pneumonia, chronic bronchitis and adult skin infections. Researchers went to the FDA with data from 11 Phase III trials involving 5,000 patients.
- read the release on the IPO